News - Pharmaphorum

Latest News

in News News

PTC shares soar after SMA drug data impresses market
June 19, 2018 Share
X
PTC shares soar after SMA drug data impresses market
https://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/
in News News

Eisai accelerates dementia drug discovery research
June 18, 2018 Share
X
Eisai accelerates dementia drug discovery research
https://pharmaphorum.com/news/eisai-dementia-drug-research/

Positive results announced for ViiV Healthcare’s two-drug HIV pill

A two-drug strategy has shown positive results, giving new hope to patients with HIV. ViiV Healthcare, which is

Positive results announced for ViiV Healthcare’s two-drug HIV pill

https://pharmaphorum.com/news/positive-results-hiv-pill/

Orphan drugs dominate 2018 UK Prix Galien shortlist

A bumper crop of orphan drugs from the likes of Amicus, Kyowa Kirin, Eusa and Biogen dominates this

Orphan drugs dominate 2018 UK Prix Galien shortlist

https://pharmaphorum.com/news/orphan-drugs-uk-prix-galien-shortlist/

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

Swiss pharma hopes to bounce back from Q1 sales disappointment

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

https://pharmaphorum.com/news/novartis-eric-hughes-cosentyx-secukinumab/

See all

More news

Brexit warning sounded on EU public health system

The UK could find its ability to counter the threat of a ‘super-gonorrhoea’ and other infectious diseases hampered

Brexit warning sounded on EU public health system

https://pharmaphorum.com/news/brexit-health-alliance-eu-ewrs/

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

https://pharmaphorum.com/news/astrazeneca-lillys-alzheimers-drug/

WuXi to build new $60m clinical and manufacturing plant

WuXi Biologics has pledged to invest $60 million into a new US-based site to expand its clinical and

WuXi to build new $60m clinical and manufacturing plant

https://pharmaphorum.com/news/wuxi-new-clinical-manufacturing-plant/

Bill and Melinda Gates start not-for-profit biotech

Biotech will focus on diseases such as TB

Bill and Melinda Gates start not-for-profit biotech

https://pharmaphorum.com/news/gates-medical-research-institute-biotech/

European Commission ploughs €100 billion into new R&D programme

The European Commission has dedicated €100 billion to its new Horizon Europe programme to fund research and innovation.

European Commission ploughs €100 billion into new R&D programme

https://pharmaphorum.com/news/european-commission-rd-programme/

Pfizer expands venture arm with $600m cash boost

Pharma giant Pfizer is injecting $600 million into its venture investment arm in a bid to ramp up

Pfizer expands venture arm with $600m cash boost

https://pharmaphorum.com/news/pfizer-expands-venture-arm-cash-boost/

Servier expands global footprint post Shire deal

Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.

Servier expands global footprint post Shire deal

https://pharmaphorum.com/news/servier-expands-footprint-shire/

More good news for AbbVie in rheumatoid arthritis

AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.

More good news for AbbVie in rheumatoid arthritis

https://pharmaphorum.com/news/abbvie-rheumatoid-arthritis/

Biotech eyes Chinese opportunities and seek local partners

Biotech companies see China as one of the biggest healthcare opportunities, but would need partnerships before approaching the

Biotech eyes Chinese opportunities and seek local partners

https://pharmaphorum.com/news/biotech-china-partnerships/

Biogen’s Alzheimer’s drug, elenbecestat, shows early promise

A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of

Biogen’s Alzheimer’s drug, elenbecestat, shows early promise

https://pharmaphorum.com/news/biogens-alzheimers-drug-elenbecestat/

Pharmaceutical Microbiology USA Event takes place in less than a week

SMi Pharma Micro West Coast USA

Pharmaceutical Microbiology USA Event takes place in less than a week

https://pharmaphorum.com/partner-content/pharmaceutical-microbiology-usa-event-takes-place-in-less-than-a-week/

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

May champions AI-backed R&D into cancer and chronic disease

Theresa May has pledged to prioritise artificial intelligence (AI) so chronic diseases are diagnosed at an early stage,

May champions AI-backed R&D into cancer and chronic disease

https://pharmaphorum.com/news/may-champions-ai-backed-rd-into-cancer-and-chronic-disease/

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-drug-dramatically-reduces-bleeds/

UCB collaborates with Science 37 on virtual clinical trials

UCB is changing the way it conducts some of its research studies, removing the need for patients to

UCB collaborates with Science 37 on virtual clinical trials

https://pharmaphorum.com/news/ucb-science-37-virtual-clinical-trials/

Search

Advanced Search

Trending

Latest News

More news